Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zenas BioPharma, Inc. Common Stock stock (ZBIO) is currently trading at $21.06. Zenas BioPharma, Inc. Common Stock PE ratio is 1.63. Zenas BioPharma, Inc. Common Stock PS ratio (Price-to-Sales) is 119.70. Analyst consensus price target for ZBIO is $42.00. WallStSmart rates ZBIO as Sell.
- ZBIO PE ratio analysis and historical PE chart
- ZBIO PS ratio (Price-to-Sales) history and trend
- ZBIO intrinsic value — DCF, Graham Number, EPV models
- ZBIO stock price prediction 2025 2026 2027 2028 2029 2030
- ZBIO fair value vs current price
- ZBIO insider transactions and insider buying
- Is ZBIO undervalued or overvalued?
- Zenas BioPharma, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- ZBIO Piotroski F-Score and Altman Z-Score
- ZBIO analyst price target and Smart Rating
Zenas BioPharma, Inc.
📊 No data available
Try selecting a different time range
ZBIO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Zenas BioPharma, Inc. Common Stock (ZBIO)
ZBIO trades at a significant discount to its Graham intrinsic value of $92.96, offering a 75% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Zenas BioPharma, Inc. Common Stock (ZBIO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Zenas BioPharma, Inc. Common Stock (ZBIO) Key Strengths (1)
70.67% of shares held by major funds and institutions
Supporting Valuation Data
Zenas BioPharma, Inc. Common Stock (ZBIO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 119.7x annual revenue
Very expensive at 6.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Zenas BioPharma, Inc. Common Stock (ZBIO) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (119.70), Price/Book (6.06) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -136.20%, Operating Margin at -2114.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -136.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZBIO's Price-to-Sales ratio of 119.70x trades 16% below its historical average of 142.2x (58th percentile). The current valuation is 71% below its historical high of 416.87x set in Nov 2025, and 1034% above its historical low of 10.56x in Dec 2024. Over the past 12 months, the PS ratio has expanded from ~87.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zenas BioPharma, Inc. Common Stock (ZBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Zenas BioPharma, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 10M with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 116M in cash.
Spending 557% of revenue (56M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -52M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Zenas BioPharma, Inc. Common Stock.
Bottom Line
Zenas BioPharma, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zenas BioPharma, Inc. Common Stock(ZBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.